Ventripoint Announces Closing of Second and Final Tranche of Non-Brokered Convertible Debenture Units Private Placement

(TheNewswire)

Toronto, Ontario, October 14,2025 – TheNewswire - Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”,TSXV:VPT) announces the issuance of anadditional $297,000 of unsecured convertible debenture units(“ Units ”) of its non-brokered private placement (the“ Offering ”) (see August 26, 2025, September 3, 2025 and October 3,2025 press releases), subject to TSXV Venture Exchange(“ Exchange ”) acceptance. Along with the issuance of $270,000 of Unitsin the first tranche, the Corporation issued an aggregate of $567,000of Units pursuant to the Offering, which was an increase from theannounced size of the Offering. Each Unit iscomprised of one (1) unsecured convertible debenture principal amountof $1,000 (“ Debentures ”) convertible into common shares(“ Common Shares ”) of the Corporation, and 9,000 common share purchasewarrants (“ Warrants ”).

The Debentures are convertible into Common Shares of the Corporation at the option of the holder at any time prior to maturity ata conversion price of $0.11 per Common Share (the “ Conversion Price ”).E ach whole Warrant will entitle the holderthereof to purchase one (1) Common Share at a price of $0.14 untilDecember 31, 2027.

The Debentures mature December31, 2027 and bear interest at ten per cent (10%)payable semi-annually in arrears in either cash or at the option ofthe Corporation by issuance of Common Shares ata 20-day VWAP market price, determined at time of payment, subject to Exchange approval.

The Corporation paid aggregate cash finder’s fees of$320 and issued an aggregate of 2,286 common share purchase warrants(“ Finder’sWarrants ”) to finders in connection with theOffering. Each Finder’s Warrant will be exercisable into one CommonShare at an exercise price of CDN$0.11 per Common Share for a periodof 18 months.

The Corporation will use the proceeds of the Offeringto fund operational costs related sales and marketing, additional keypersonnel, and general working capital purposes.

All securities issued pursuant to the Offering aresubject to a hold period of four months plus one day from the date ofclosing of the Offering. The Offering is subject to approval of theExchange.

The securities offered will not beregistered under the U.S. Securities Act of 1933, as amended, and maynot be offered or sold in the United States absent a registrationstatement or an applicable exemption from the registrationrequirements. The press release shall not constitute an offer to sellor the solicitation of an offer to buy nor shall there be any sale ofthe securities in any State in which such offer, solicitation or salewould be unlawful.

About Ventripoint DiagnosticsLtd.

Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS+ products are powered by itsproprietary knowledge-based reconstructiontechnology, which is the result of a decade of development andprovides accurate volumetric cardiac measurements equivalent to MRI.This affordable, gold-standard alternative allows cardiologistsgreater confidence in the management of their patients. Providingbetter care to patients serves as a springboard and basic standard forall of Ventripoint's products that guide our future developments.In addition, VMS+ is versatile and can be used with all ultrasoundsystems from any vendor supported by regulatory market approvals inthe U.S., Europe and Canada.

For further information, pleasecontact:

Hugh MacNaught

hmacnaught@ventripoint.com

604-671-4201

Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' andsimilar expressions are intended to identify forward-lookinginformation or statements. The forward-looking statements andinformation are based on certain key expectations and assumptions madeby the Corporation. Although the Corporation believes that theexpectations and assumptions on which such forward-looking statementsand information are based are reasonable, undue reliance should not beplaced on the forward-looking statements and information because theCorporation can give no assurance that they will prove to becorrect.

Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in theCorporation's most recent annual management's discussion andanalysis that is available on the Corporation's profile on SEDAR+at www.sedarplus.ca. Readers are cautioned that the foregoing list of factors isnot exhaustive. The forward-looking statements included in this newsrelease are expressly qualified by this cautionary statement. Theforward-looking statements and information contained in this newsrelease are made as of the date hereof and the Corporation undertakesno obligation to update publicly or revise any forward-lookingstatements or information, whether as a result of new information,future events or otherwise, unless so required by applicablesecurities laws.

NOT FOR DISTRIBUTION TOUNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITEDSTATES

Copyright (c) 2025 TheNewswire - All rights reserved.